Back to top

Image: Bigstock

Ahead of Medtronic (MDT) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Read MoreHide Full Article

In its upcoming report, Medtronic (MDT - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.34 per share, reflecting a decline of 1.5% compared to the same period last year. Revenues are forecasted to be $9.46 billion, representing a year-over-year increase of 5.6%.

The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

In light of this perspective, let's dive into the average estimates of certain Medtronic metrics that are commonly tracked and forecasted by Wall Street analysts.

The consensus estimate for 'Net Sales- World Wide Revenue- Neuroscience' stands at $2.66 billion. The estimate indicates a change of +3.8% from the prior-year quarter.

Based on the collective assessment of analysts, 'Net Sales- World Wide Revenue- Cardiovascular' should arrive at $3.77 billion. The estimate indicates a year-over-year change of +9.6%.

It is projected by analysts that the 'Net Sales- World Wide Revenue- Other' will reach $19.75 million. The estimate indicates a year-over-year change of -43.6%.

Analysts expect 'Net Sales- World Wide Revenue- Medical Surgical' to come in at $2.21 billion. The estimate points to a change of +1.7% from the year-ago quarter.

According to the collective judgment of analysts, 'Net Sales- World Wide Revenue- Diabetes' should come in at $822.11 million. The estimate suggests a change of +8.6% year over year.

The collective assessment of analysts points to an estimated 'Net Sales- World Wide Revenue- Neuroscience- Neuromodulation' of $537.52 million. The estimate indicates a change of +3.4% from the prior-year quarter.

The combined assessment of analysts suggests that 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' will likely reach $1.36 billion. The estimate suggests a change of +4.6% year over year.

Analysts predict that the 'Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies' will reach $776.37 million. The estimate suggests a change of +4.4% year over year.

The consensus among analysts is that 'Net Sales- World Wide Revenue' will reach $8.62 billion. The estimate points to a change of -3.8% from the year-ago quarter.

Analysts' assessment points toward 'Net Sales- World Wide Revenue- Medical Surgical- Acute Care & Monitoring(' reaching $507.80 million. The estimate suggests a change of +3% year over year.

The average prediction of analysts places 'Net Sales- U.S. Revenue' at $4.85 billion. The estimate indicates a change of +7.5% from the prior-year quarter.

Analysts forecast 'Net Sales- International' to reach $4.62 billion. The estimate indicates a change of +3.9% from the prior-year quarter.

View all Key Company Metrics for Medtronic here>>>

Shares of Medtronic have demonstrated returns of +8.3% over the past month compared to the Zacks S&P 500 composite's -4.3% change. With a Zacks Rank #3 (Hold), MDT is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Published in